Cover Image
市場調查報告書

黏蛋白1:開發中產品分析

Mucin 1 - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364856
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
黏蛋白1:開發中產品分析 Mucin 1 - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 80 Pages
簡介

本報告提供以黏蛋白1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

黏蛋白1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Akshaya Bio Inc.
  • Boehringer Ingelheim GmbH
  • Etubics Corporation
  • Merck KGaA
  • Minerva Biotechnologies Corporation
  • Transgene SA
  • Vaxil Bio Therapeutics Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0905TDB

Title:
Mucin 1(Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2017.

Summary:

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 21 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Mucin 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colon Cancer, Lung Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenomas, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Solid Tumor.

Furthermore, this report also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
  • The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Overview
    • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc
    • Bavarian Nordic A/S
    • Boehringer Ingelheim GmbH
    • Etubics Corp
    • GeoVax Labs Inc
    • Merck KGaA
    • Minerva Biotechnologies Corp
    • Transgene SA
    • Vaxil Bio Therapeutics Ltd
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles
    • BI-1361849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MUC1 for Gastric Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GO-203/NPs - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GO-2032c - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ImMucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tecemotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-4010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 1 to Target MUC-1 Protein for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 2 to Target MUC-1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 3 to Target MUC-1 Protein for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC-1 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target MUC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Mucin 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Products
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products
  • Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2017: Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials
      • Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer
      • Mar 13, 2017: First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer
      • Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer
      • Mar 03, 2017: Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting
      • Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer
      • Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer
      • Dec 07, 2016: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
      • Nov 29, 2016: Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin
      • Aug 15, 2016: Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study
      • Aug 04, 2016: Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy
      • Jun 16, 2016: Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin
      • Apr 20, 2016: Studies published in "Oncogene" demonstrate that MUC1-C regulates DNA methylation in human carcinoma cells
      • Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine
      • Mar 16, 2016: Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Akshaya Bio Inc, H2 2017
  • Pipeline by Bavarian Nordic A/S, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Etubics Corp, H2 2017
  • Pipeline by GeoVax Labs Inc, H2 2017
  • Pipeline by Merck KGaA, H2 2017
  • Pipeline by Minerva Biotechnologies Corp, H2 2017
  • Pipeline by Transgene SA, H2 2017
  • Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top